🔴 BLAZE-1 Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
Among high-risk ambulatory patients, bamlanivimab plus etesevimab led to a lower incidence of Covid-19–related hospitalization and death than did placebo and accelerated the decline in the SARS-CoV-2 viral load.
🔴 A ‘mix and match’ approach to SARS-CoV-2 vaccination
Heterologous dosing with the adenovirus-based ChAdOx1 (AstraZeneca) vaccine followed by an mRNA vaccine induced stronger immune responses than did the homologous ChAdOx1 vaccine series, according to recent immunogenicity studies.
🔵 Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
Covid-19 vaccines in the United States were highly effective against SARS-CoV-2 infection requiring hospitalization, ICU admission, or an emergency department or urgent care clinic visit. This vaccine effectiveness extended to populations that are disproportionately affected by SARS-CoV-2 infection.
🔵 Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
🔵 Myocarditis after Covid-19 Vaccination in a Large Health Care Organization
Among patients in a large Israeli health care system who had received at least one dose of the BNT162b2 mRNA vaccine, the estimated incidence of myocarditis was 2.13 cases per 100,000 persons; the highest incidence was among male patients between the ages of 16 and 29 years. Most cases of myocarditis were mild or moderate in severity.